BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q4 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $107.9 million versus the consensus estimate of $115.3 million.

Sees FY2012 revenue of $465-$510 million, versus the consensus of $512.6 million.

For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.

Earnings Guidance Hot Guidance